Hype against randomized trials for one topic, computed and dated 30 October 2026. It rates the topic, never a person, and gives no dosing and no sourcing.
The short version
145Kyearly wiki viewsEnglish Wikipedia, to 30 Sep 2026
52randomized-trial paperstyped on PubMed
2,785views per trial paperlower is better backed
Hype is nudging aheadthe verdictby the published rule
Niacinamide
Hype is nudging ahead
2,785yearly views per trial paper
hype145K views a yearproof52 trial papers
Trials exist, but attention is running a step ahead of the record.
English Wikipedia readers opened the Niacinamide article about 145K times in the year to 30 September 2026. PubMed holds 52 papers typed as randomized trials for it, which is 2,785 yearly views per trial paper. By the published rule that earns the verdict Hype is nudging ahead.
That is a statement about the gap between attention and trial record. It does not say whether Niacinamide works or whether it is safe for anyone.
How does it compare with the others?
Niacinamide next to the other fourhype above, proof below, read 30 October 2026
Top chart: attention. Bottom chart: randomized-trial papers typed on PubMed. The highlighted bar is Niacinamide. A big top bar over a small bottom bar is what the meter reads as hype ahead of the trials.